This activity provides targeted education to community pharmacists and managed health care professionals for the emerging therapies on the horizon in moderate-to-severe atopic dermatitis (AD) and alopecia areata (AA). Also included are brief vignettes of actual patient interviews. Their perspectives will provide insight into the daily challenges and quality of life issues that can occur while living with AD and AA.

Our experts discuss the connection between AD and AA and compare/contrast their differences; the challenges surrounding the available treatments for AD and AA, with a large unmet need for alternative and more effective therapies with a good safety profile for long-term use; how the Janus kinase (JAK)-signal transducer activator of transcription pathways have an important role in the pathogenesis of AD and AA; the latest clinical trial efficacy, safety, and tolerability data of available and emerging oral JAK inhibitors currently under investigation for AD and AA; and the potential place in therapy and monitoring aspects for the emerging agents in AD and AA.

Furthermore, the experts discuss how the health disparities of patients with AA and/or AD leads to lower medication access and they explore the unique role of the pharmacist in providing education and obtaining prior authorization to medications for patients with AA and/or AD.